The first IL-23 inhibitor for psoriasis arthritis, Jansen Tremfya, was approved by the FDA.

Psoriasis arthritis is a chronic inflammatory disease that can lead to irreversible joint deformation and disabilityIt is estimated that there are more than 50 million people with psoriasis arthritis worldwidePsoriasis arthritis usually occurs first in the finger and toe joints, causing swelling and pain in the joints and affecting joint movement, as well as nail and toenail lesionsOther joints in patients with serious illness can also be affected, seriously hampering motor functionTremfya (guselkumab) is a specific anti-IL-23 monoclonal antibody developed by Jansen that blocks IL-23 action by binding to the p19 subkey of IL-23In 2017, Tremfya received FDA approval to treat adult patients with moderate-severe plaque psoriasisIn December 2019, guselkumab (universal name Gusechi Yusa, commodity name: Tenoya) was approved in China for use in adult patients with moderate to severe plaque psoriasis suitable for systematic treatmentTremfya's approval is based on two key Phase 3 clinical trials, DISCOVER-1 DISCOVERAND and -2Recent results published in the Lancet showed that in the DISCOVER-1 and DISCOVER-2 trials, patients treated with Tremfya reached the study's primary endpoint (ACR20) at 24 weeks at 52 percent and 64 percent, respectively, compared with 22 percent and 33 percent of those treated with placebosDr David MLee, head of immunology therapy at Jansen, said: "Tremfya is the only selective IL-23 inhibitor approved for the treatment of active psoriasis arthritis and moderate to severe plaque dandruff, and the only approved biological product for the treatment of psoriasis arthritisToday's approval marks an exciting milestoneReferences: tREMFYA ® (guselkumab) Approved by U.SFood and Drug And Drug as The First First Selective Interleukin (IL)-23 for Active Psoriatic ArthritisRetrieved 2020-07-14, from